The Fast Money traders take a look at today's biggest market movers.» Read More
So, imagine my surprise when Amgen put out a press release this morning with new financial guidance. You can read it for yourself here. The release was issued in conjunction with the company's presentation at the JPMorgan Healthcare Conference.
Bear Stearns' management shake-up could make the investment bank a takeover target, but the specter of more write-downs might keep suitors on the sidelines.
After the closing bell Monday, Genzyme and Isis Pharmaceuticals announced a blockbuster deal that set the overcrowded halls abuzz here at the JPMorgan Healthcare Conference. They're partnering on an Isis drug in late-stage development for cholesterol. It's a once-a-week injectable for people who don't get their cholesterol low enough taking a statin like Lipitor, Crestor or Zocor.
He's back 'for the long term.' The man who commercialized the gourmet cafe brand and convinced the world to pay $5+ for a cup of specialty coffee is returning to the CEO seat. Howard Schultz is once again the CEO at Starbucks and says that he plans to recaffeinate sales and perk up the coffee giants' sagging stock price.
Slowdown talk hurts tech, commodities, defense stocks today. UBS downgrades IBM on concerns about a slowing in tech orders; Deutsche Bank downgrades Boeing and Goodrich. Commodities weak across the board—metals, steel, iron ore (2nd day in a row.) Defensive stocks—consumer, drugs all strong. Lilly upgraded at Morgan Stanley.
Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.
Krispy Kreme Doughnuts said on Monday that Chief Executive Daryl G. Brewster has resigned for personal reasons and will be replaced by its Chairman James H. Morgan as president and CEO.
It still hasn't been built and it may not hit showrooms by the time people have been projecting. Yet, it's causing a puzzling amount of angst for investors and auto fans. I'm talking about the Chevy Volt, an electrically driven car GM is developing.
While many banks are reeling from the no-money-down borrowers who reneged on their home loans, it’s business as usual for this lender.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
The Food and Drug Administration late this morning put out a news release with the heading, "FDA Receives New data on Risks of Anemia Drugs." This is more bad news for an additional population of cancer patients and, of course, Amgen and, to a lesser extent, Johnson and Johnson.
Maybe it's because of the Iowa caucus' taking place Wednesday night. Maybe it's because at the start of a new year, it's a good time to make predictions. Or maybe it's because the auto show season is about to kick off with the automakers putting out their visions for the future. Whatever the reason, I think today is the day to ask YOU which automaker has the most to show, prove, gain, lose in 2008?
The credit crunch and housing crisis led to some high-profile firings, most notably Merrill Lynch's Stan O'Neal and Citigroup's Chuck Prince. Still, while they lost their jobs, these executives didn't lose their shirts.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
With Detroit and much of the auto industry shut down this week and gearing up for the Detroit Auto Show next month, I thought it would be a good time to take a few minutes and share my Christmas wishes for the auto world. I hope Santa brings you everything you want.
Yes, I'd rather be blogging about another topic by now, but I hope this will be the last entry -- at least for awhile -- on the Avastin vs. Lucentis story. You see, last Friday I got repeatedly voice-mailed and e-mailed by Christine Castro, the new head of corporate communications/media relations at Genentech...
MBIA CEO Gary Dunton "has the touch of a great novelist" when it comes to the company's financial reports, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Thanks to quantitative models, this fund has eliminated human emotion from its investment decisions.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.
Occasionally, when I state my opinion about a particular car or automaker, I get swamped with e-mails from people who think I'm an idiot. Yesterday was one of those days: I was talking about the new Corvette ZR1...
Network equipment maker Cisco Systems said Chief Development Officer Charles Giancarlo, widely seen as a leading candidate for future CEO, is leaving the company.